Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Commission File Number: 001-36439 | | --- | PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics - Revenue grew by almost 30% quarter-over-quarter and doubled year-over-year, reaching $4.5 million in Q3 2023, putting the company on an annualized run rate of $18 million [8] - Cash burn dropped to around $1 million in Q3 2023, down approximately 40% from $2.5 million in the same quarter of the previous year [9] - The Pathology division reached a cash-neutral status, achieving a breakeven run rate of $14 million, while the Product division is on track to reach a reduced breakeven threshold of $6 million annually ($1.5 million per quarter) [13][15] Business Line Performance - Both the Pathology and Product businesses contributed to the revenue growth, with the Pathology division now operating as a cash-neutral entity [8][13] - The Product division has not yet reached its $8 million target but is expected to achieve a revised breakeven threshold of $6 million annually due to operational efficiencies [15] Market and Strategic Direction - The company's strategy focuses on developing and selling diagnostic products for laboratories, leveraging its cash-neutral Pathology division as a cost-free R&D center [18][19] - The release of the BCR-ABL assay in August 2023, developed at a cost of less than $100,000, exemplifies the company's low-cost product development model [20] - The total available market potential for products like HemeScreen is estimated at $400 million annually, with significant growth potential [23] Management Commentary on Operating Environment and Future Outlook - Management emphasized the importance of maintaining a frugal mindset even after achieving breakeven, highlighting operational efficiencies such as bringing billing functions in-house, which saves $50,000 to $75,000 monthly [14][17] - The company plans to focus on financial stability, product growth, and R&D development in 2024, including expanding the HemeScreen product line and developing new products [24][26] - Management intends to increase investor outreach through conferences, social media, and digital marketing campaigns to raise awareness of the company's financial success and growth potential [27] Other Key Information - The company believes it has sufficient cash reserves to achieve financial independence, even if it takes one or two more quarters to reach the target [16] - Investments in sales and marketing, as well as product production lines, are expected to yield positive ROI within 12 months, further improving business economics [21][22] Q&A Session - No specific questions or answers were provided in the transcript [30]

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

Precipio, Inc. (NASDAQ:PRPO) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) incorporation or organization) Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant ...

Precipio, Inc. (NASDAQ:PRPO) Q1 2023 Earnings Conference Call May 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 i ...

Precipio, Inc. (NASDAQ:PRPO) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Operator Welcome to the Precipio Shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking stateme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Commission File Number: 001-36439 | | | --- | --- | | PRECIPIO, | INC. | | (Exact name of registrant as specified in its charter) | | | Delaware | 91-1789357 | | (State or ot ...

Precipio, Inc. (NASDAQ:PRPO) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Shareholder Third Quarter 2022 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this contain forward-looking statements about our business. You should not place undue r ...